KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income: 2019-2024

Historic Net Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$463.7 million.

  • Recursion Pharmaceuticals' Net Income fell 69.29% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 89.42%. This contributed to the annual value of -$463.7 million for FY2024, which is 41.33% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Net Income of -$463.7 million as of FY2024, which was down 41.33% from -$328.1 million recorded in FY2023.
  • Recursion Pharmaceuticals' 5-year Net Income high stood at -$84.6 million for FY2020, and its period low was -$463.7 million during FY2024.
  • In the last 3 years, Recursion Pharmaceuticals' Net Income had a median value of -$328.1 million in 2023 and averaged -$343.7 million.
  • Data for Recursion Pharmaceuticals' Net Income shows a maximum YoY tumbled of 120.39% (in 2021) over the last 5 years.
  • Over the past 5 years, Recursion Pharmaceuticals' Net Income (Yearly) stood at -$84.6 million in 2020, then plummeted by 120.39% to -$186.5 million in 2021, then dropped by 28.42% to -$239.5 million in 2022, then tumbled by 36.99% to -$328.1 million in 2023, then plummeted by 41.33% to -$463.7 million in 2024.